Neutrophils, once considered simple foot soldiers of innate immunity, are now recognized as complex players in cancer.

Liver metastasis is a life-threatening complication of colorectal cancer (CRC), yet its molecular underpinnings remain elusive.

Researchers at Nagoya University in Japan have developed a lipid nanoparticle that delivers mRNA to cells five times more effectively. By attaching a sulfur-containing ring structure—a cyclic disulfide—to lipid molecules, they found that significantly more mRNA can escape from cell components that normally destroy genetic material. When tested as a cancer vaccine in mice, the new delivery system stopped tumor growth. The study, published in the journal RSC Medicinal Chemistry, demonstrates the first successful use of cyclic disulfide-containing lipids to improve mRNA delivery in animals and suppress tumor growth.

The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition considered incurable without transplantation, according to a new clinical study led by researchers at Sylvester Comprehensive Cancer Center.

Researchers at EPFL have discovered how the structure of DNA packaging in cells determines which proteins can interact with the key tumor suppressor p53.

In the same vein as weather forecast models that predict developing storms, researchers now have developed a method to predict the cell activity in tissues over time.  The new software combines genomics technologies with computational modeling to predict cell changes in behavior, such as communication between cells that could cause cancer cells to flourish.

Immunotherapy has shown tremendous potential in cancer treatment but remains ineffective for most patients. Researchers continue to develop new therapeutic strategies to enhance both the safety and treatment efficacy of immunotherapy. A commentary authored by the group of Bo Xiao and Chenghui Wang at University of Electronic Science and Technology of China introduces a new strategy combining systemic type I interferons (IFN-I) with topical Toll-like receptor 7/8 (TLR7/8) agonists to enhance the antitumor effect of PD-1 antibodies. The commentary, titled “Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors,” was published in Research.